Market Exclusive

ABIOMED, Inc. (NASDAQ:ABMD) gets downgraded to Neutral by BTIG Research

Analyst Ratings For ABIOMED, Inc. (NASDAQ:ABMD)

Today, ABIOMED, Inc. (NASDAQ:ABMD) stock was downgraded by BTIG Research from Buy to Neutral.

There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ABIOMED, Inc. (NASDAQ:ABMD) is Buy with a consensus target price of $400.3333 per share, a potential 98.39% upside.

Some recent analyst ratings include

About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. Read More…

Recent Trading Activity for ABIOMED, Inc. (NASDAQ:ABMD)
Shares of ABIOMED, Inc. closed the previous trading session at 202.21 −76.35 27.41% with shares trading hands.

Exit mobile version